Tubulis
Christoph Broja is a seasoned finance and investment professional currently serving as Managing Director at EQT Life Sciences and as a Board Member at Cardior Pharmaceuticals since September 2022. Prior experience includes roles as Principal and Senior Associate at Gurnet Point Capital from August 2016 to June 2022, along with various board positions, including Board Observer at Innocoll Biotherapeutics and Boston Pharmaceuticals, and Board Member at Tremeau Pharmaceuticals, Inc. from March 2019 to June 2022. Christoph also contributed as a Business Partner at B-FLEXION and held the position of Senior Analyst at Franz Haniel & Cie. GmbH. Christoph Broja is an alumnus of Friedrich Schiller University Jena.
This person is not in the org chart
This person is not in any teams
This person is not in any offices
Tubulis
2 followers
Tubulis generates uniquely matched protein-drug conjugates by combining proprietary novel technologies with disease-specific biology. Their goal is to expand the therapeutic potential of antibody-drug conjugates (ADCs) ushering in a new era and delivering better outcomes for patients. They will advance a range of conjugates, unlimited by indication, using their own discovery capabilities and by solving development challenges for partners with both antibody and chemical assets.